Overall survival rate has nearly doubled for Ph+ ALL patients after hematopoietic stem cell transplant

By | January 13, 2022
For patients with acute lymphoblastic leukemia (ALL) carrying the Philadelphia chromosome and whose disease relapsed after allogeneic hematopoietic stem cell transplantation (HCT), the two-year overall survival rate has nearly doubled from the period between 2000 and 2004 to the period between 2015 and 2019.